Drug development industry stakeholders recognise there is no one-size-fits-all approach to the long-standing challenge of patient recruitment and engagement.
Artificial intelligence (AI) and machine learning are here to stay, so it’s crucial to understand how they can be used to the best effect in the evolving world of clinical trials.<
Debiopharm Innovation Fund, the Swiss biopharma’s strategic investing arm managing a $150 million fund, is looking to get involved earlier in the investment process with the launch of a new
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl